Stock Price Quote

KREBS BIOCHEMICALS & INDUSTRIES LTD.

NSE : KREBSBIOBSE : 524518ISIN CODE : INE268B01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE71.76-0.84 (-1.16 %)
PREV CLOSE ( ) 72.60
OPEN PRICE ( ) 72.61
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1637
TODAY'S LOW / HIGH ( )68.40 74.50
52 WK LOW / HIGH ( )59.3 93.2
NSE72.20-0.2 (-0.28 %)
PREV CLOSE( ) 72.40
OPEN PRICE ( ) 74.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3049
TODAY'S LOW / HIGH( ) 71.55 74.70
52 WK LOW / HIGH ( )59.2 93.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 02-12 1991
Management Info
R T Ravi - Chairman Jitendra Shah - Managing Director
Registered Office

Address Kothapalli Village,Anakapalli,Kasimkota Mandal,
Vishakhapatnam,
Andhra Pradesh-531031

Phone 040-66808040 / 9121144984

Email marketing@krebsbiochem.com / investors@krebsbiochem.com

Website www.krebsbiochem.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

17Jan Appointment of Company Secretary and
The Board of Directors of the Company in its Meeting held today has app..
09Jan Krebs Biochemicals & Industries inform
In Compliance with Regulation 74(5) of SEBI (Depositories and Participan..
08Sep Krebs Biochemicals & Industries inform
Krebs Biochemicals & Industries has informed regarding issue of Lett..
31Aug Krebs Biochemicals and Industries info
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosur..
18Mar Krebs Biochemicals and Industries info
Further to its letter dated February 13, 2023, Postal Ballot Notice (‘No..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-49.77-246.91
Gross Profit -49.77 -246.91
Operating Profit -20.6-151.59
Net Sales 129.77521.34

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2660.60 (7.35%)
M.Cap ( in Cr)1643.73
Glaxosmithkline Phar (BSE)
peergroup  2070.35 (6.57%)
M.Cap ( in Cr)35072.98
TTK Healthcare (BSE)
peergroup  1620.30 (7.69%)
M.Cap ( in Cr)2289.54
Sanofi India (BSE)
peergroup  8209.85 (0.82%)
M.Cap ( in Cr)18907.80
Cipla (BSE)
peergroup  1400.00 (3.88%)
M.Cap ( in Cr)113035.30

Shareholding Pattern

PROMOTERS 72.74%
NON-INSTITUTION 26.76%
FII 0.01%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%

About Krebs Biochemicals & Industries Ltd.

Krebs Biochemicals & Industries Ltd. was incorporated in the year 1991. Its today's share price is 71.76. Its current market capitalisation stands at Rs 154.72 Cr. In the latest quarter, company has reported Gross Sales of Rs. 521.34 Cr and Total Income of Rs.527.55 Cr. The company's management includes Pabitrakumar Kalipada Bhattacharyya, Avinash Ravi, Satish Khivsara, Tangirala Malati, Raj Kamal Prasad Verma, GVL Prasad, Jitendra Shah, R T Ravi.

It is listed on the BSE with a BSE Code of 524518 , NSE with an NSE Symbol of KREBSBIO and ISIN of INE268B01013. It's Registered office is at Kothapalli Village,Anakapalli,Kasimkota MandalVishakhapatnam-531031, Andhra Pradesh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhavani & Co, Pavuluri & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.